Study guide
10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings
Certified Burn Registered Nurse CBRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Foundations of Burn Care
1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones
2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response
2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology
3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria
3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics
4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)
4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy
5 Chapter 5: Airway Management & Inhalation Injury Management
5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)
6 Chapter 6: Acute Multisystem Assessment & Critical Care Management
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection
7 Chapter 7: Hypermetabolism & Nutritional Support
7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation
8 Chapter 8: Pain Management in Burn Care
8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction
9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus
9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients
10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings
10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances
11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure
11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management
12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy
12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion
13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries
13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy
14 Chapter 14: Special Burn Populations & Cutaneous Syndromes
14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries
15 Chapter 15: Rehabilitation, Scar Management & Reconstruction
15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management
16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage
16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response
10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings
Key Takeaways Explain This Topic AI
Prophylactic systemic antibiotics do not penetrate avascular, non-perfused burn eschar and are strictly contraindicated; topical antimicrobial agents provide high local tissue concentrations to control bacterial bioburden and prevent invasive burn wound sepsis.
Silver Sulfadiazine 1% (Silvadene) is a broad-spectrum, painless topical agent that is surface-active only (does not penetrate intact eschar); it forms a gelatinous pseudoeschar requiring mechanical removal, induces transient reversible leukopenia, and is contraindicated in sulfa allergy, near-term pregnancy, and infants <2 months (kernicterus).
Mafenide Acetate (Sulfamylon) 8.5% cream or 5% aqueous solution possesses exceptional eschar and cartilaginous penetration (drug of choice for deep eschar and ear/nose burns to prevent suppurative chondritis); however, it causes intense burning pain and is a carbonic anhydrase inhibitor that can trigger hyperchloremic metabolic acidosis and compensatory tachypnea.
Silver Nitrate 0.5% aqueous solution is a painless, broad-spectrum wet soak with zero eschar penetration; its marked hypotonicity leaches electrolytes from open wounds causing severe hyponatremia and hypochloremia, stains skin and linens black, and rarely causes methemoglobinemia from bacterial nitrate reduction.
Modern nanocrystalline silver dressings (e.g., Acticoat, Aquacel Ag, Mepilex Ag) deliver sustained bioactive silver ion (Ag+) release over 3 to 7 days, reducing dressing changes; they must ALWAYS be activated/moistened with sterile water, NEVER 0.9% normal saline, which precipitates active silver into insoluble, inert silver chloride (AgCl).
Last updated: August 2026
10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings
Core Knowledge: The loss of the epidermal stratum corneum barrier combined with the presence of avascular, necrotic burn eschar creates an optimal environment for microbial proliferation. Systemic antibiotics cannot reach the non-perfused eschar through the thrombosed microcirculation. Therefore, topical antimicrobial therapy forms the cornerstone of non-surgical burn wound management to suppress bacterial colonization and prevent lethal invasive burn wound sepsis.
1. Rationale: Topical vs. Systemic Antimicrobial Therapy
A critical tenet of burn critical care nursing is that prophylactic systemic antibiotics are strictly contraindicated in burn management . Administering intravenous prophylactic antibiotics fails to deliver therapeutic concentrations into the avascular eschar, destroys normal endogenous flora, and rapidly selects for multi-drug resistant (MDR) superinfections (e.g., Carbapenem-resistant Pseudomonas aeruginosa , MRSA, VRE, Acinetobacter baumannii , and Candida spp.). AVASCULAR ESCHAR VS. ANTIMICROBIAL DELIVERY
- ┌────────────────────────────────────────────────────────────────────────┐
- │ Intravenous Antibiotics ──► Circulate in Patent Systemic Vasculature │
- │ │ │
- │ ▼ │
- │ Microvascular Thrombosis in Burn Eschar Blocks Systemic Delivery │
- │ [Result: Zero therapeutic antibiotic concentrations in necrotic tissue]│
- ├────────────────────────────────────────────────────────────────────────┤
- │ Topical Antimicrobial Agents ──► Direct Surface Application │
- │ │ │
- │ ▼ │
- │ High local concentration gradients suppress bioburden across eschar │
- │ [Result: Prevents bacterial density from exceeding >10^5 CFU/g] │
- └────────────────────────────────────────────────────────────────────────┘
Systemic antibiotics are indicated only for clinically documented systemic burn sepsis, targeted bacteremia, pneumonia, urinary tract infections, or during perioperative surgical excision coverage.
2. Silver Sulfadiazine 1% (Silvadene / SSD)
Silver Sulfadiazine 1% is a water-soluble cream combining silver nitrate and sodium sulfadiazine. It has historically been the most widely used topical burn agent. SILVER SULFADIAZINE 1% (SSD) PROFILE
- ┌───────────────────────┬────────────────────────────────────────────────────────┐
- │ Antimicrobial Spectrum│ Broad: Gram-positive (S. aureus), Gram-negative │
- │ │ (P. aeruginosa, E. coli, Klebsiella), and Candida spp. │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Tissue Penetration │ POOR / SURFACE ACTIVE ONLY. Does NOT penetrate thick, │
- │ │ intact, or leathery eschar. │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Application Technique │ Apply 1/16-inch (2–3 mm) layer 1 to 2 times daily; │
- │ │ painless and soothing upon initial contact. │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Adverse Effects & │ • Transient, reversible leukopenia (nadir at 48–72h) │
- │ Contraindications │ • Forms gelatinous yellowish-grey "pseudoeschar" │
- │ │ • Contraindicated in Sulfa allergy │
- │ │ • Contraindicated in pregnancy near term & infants <2mo│
- │ │ • Retards epidermal re-epithelialization │
- └───────────────────────┴────────────────────────────────────────────────────────┘
Critical Nursing & Pharmacological Considerations for SSD:
Transient Leukopenia: Up to 15% to 30% of patients develop a transient, benign drop in white blood cell (WBC) count ( W B C < 3 , 000 – 4 , 000 / μ L WBC < 3,000–4,000/\mu L W BC < 3 , 000–4 , 000/ μL with absolute neutrophil count [ A N C ] < 1 , 500 / μ L [ANC] < 1,500/\mu L [ A NC ] < 1 , 500/ μL ), reaching a nadir 48 to 72 hours after therapy initiation. This represents margination of circulating neutrophils into the burn wound margin rather than true bone marrow suppression. It typically resolves spontaneously even with continued SSD application; however, if the WBC falls below 2 , 000 / μ L 2,000/\mu L 2 , 000/ μL , SSD should be temporarily held and switched to an alternative agent.
Pseudoeschar Formation: SSD reacts with serum exudate to form a soft, yellowish-grey, gelatinous proteinaceous layer called pseudoeschar . Bedside nurses must completely wash and gently debride this pseudoeschar during daily hydrotherapy before reapplying fresh SSD, as the pseudoeschar can trap bacteria and be easily misidentified as wound infection.
Kernicterus Risk: Sulfonamides displace bilirubin from albumin-binding sites. In pregnant patients near term or infants under 2 months of age , unconjugated bilirubin crosses the immature blood-brain barrier, precipitating fatal kernicterus (bilirubin encephalopathy).
Inhibition of Keratinocyte Migration: SSD is cytotoxic to regenerating keratinocytes and fibroblasts in vitro, delaying spontaneous re-epithelialization. Consequently, modern burn protocols avoid SSD on clean, superficial partial-thickness burns, donor sites, and newly applied skin autografts.
3. Mafenide Acetate (Sulfamylon 8.5% Cream & 5% Aqueous Solution)
Mafenide acetate is a methylated sulfonamide compound with unique physical and pharmacological properties that make it indispensable for high-risk, deep burns. MAFENIDE ACETATE (SULFAMYLON) PROFILE
- ┌───────────────────────┬────────────────────────────────────────────────────────┐
- │ Antimicrobial Spectrum│ Exceptional broad-spectrum: Gram-positives, Gram- │
- │ │ negatives (Pseudomonas), and anaerobes (Clostridium). │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Tissue Penetration │ SUPERIOR / DEEP ESCHAR PENETRATION. Penetrates dense, │
- │ │ avascular eschar and poorly vascularized cartilage. │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Primary Indications │ • Heavily contaminated, deep full-thickness burns │
- │ │ • Deep burns to the ears and nose (prevents suppurative│
- │ │ auricular/nasal chondritis) │
- │ │ • 5% aqueous solution used to wet-soak meshed grafts │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Major Adverse Effects │ • Severe, burning application pain (lasts 20–60 min) │
- │ │ • Carbonic Anhydrase Inhibition ──► Metabolic Acidosis │
- │ │ • Hypersensitivity rash in 5% of patients │
- └───────────────────────┴────────────────────────────────────────────────────────┘
Pathophysiology of Mafenide Acetate Metabolic Acidosis:
Mafenide acetate and its primary metabolite ( p-carboxybenzenesulfonamide ) are potent inhibitors of renal carbonic anhydrase . Carbonic Anhydrase Blockade ⟶ Decreased Renal H C O 3 − Reabsorption ⟶ Renal Bicarbonate Wasting ⟶ Hyperchloremic Normal Anion Gap Metabolic Acidosis \text{Carbonic Anhydrase Blockade} \longrightarrow \text{Decreased Renal } HCO_3^- \text{ Reabsorption} \longrightarrow \text{Renal Bicarbonate Wasting} \longrightarrow \text{Hyperchloremic Normal Anion Gap Metabolic Acidosis} Carbonic Anhydrase Blockade ⟶ Decreased Renal H C O 3 − Reabsorption ⟶ Renal Bicarbonate Wasting ⟶ Hyperchloremic Normal Anion Gap Metabolic Acidosis
Compensatory Response: The respiratory center in the brainstem detects systemic acidemia, triggering compensatory hyperventilation and tachypnea ( R R > 28 – 36 breaths/min RR > 28–36\text{ breaths/min} RR > 28–36 breaths/min ; blowing off C O 2 CO_2 C O 2 to decrease P a C O 2 PaCO_2 P a C O 2 ).
Nursing Action: If a patient receiving Sulfamylon cream develops tachypnea, obtain an Arterial Blood Gas (ABG). If metabolic acidosis is present ( p H < 7.30 , H C O 3 − < 16 mEq/L pH < 7.30, HCO_3^- < 16\text{ mEq/L} p H < 7.30 , H C O 3 − < 16 mEq/L with respiratory compensation), wash off the Sulfamylon cream immediately , apply an alternative topical agent (e.g., silver nitrate or nanocrystalline silver), and monitor for resolution of acid-base derangements.
Procedural Pain Management: Application of Sulfamylon cream causes intense stinging and burning that peaks within 15 to 30 minutes. Preemptive IV opioid and adjuvant administration 20 to 30 minutes prior to dressing changes is mandatory.
4. Silver Nitrate 0.5% Aqueous Solution
Silver nitrate ( A g N O 3 AgNO_3 A g N O 3 ) 0.5% is an inorganic chemical agent applied as continuous wet soaks. SILVER NITRATE 0.5% AQUEOUS SOLUTION
- ┌───────────────────────┬────────────────────────────────────────────────────────┐
- │ Antimicrobial Spectrum│ Broad spectrum: Gram-positive, Gram-negative, & fungi. │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Eschar Penetration │ ZERO ESCHAR PENETRATION. Surface active only; silver is│
- │ │ instantly precipitated by wound surface proteins. │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Application Technique │ Applied via multi-layered (6–8 ply) gauze saturated │
- │ │ with 0.5% solution. Gauze must be kept continuously │
- │ │ moist by re-saturating every 2 hours; changed q12–24h. │
- ├───────────────────────┼────────────────────────────────────────────────────────┤
- │ Adverse Effects & │ • Severe electrolyte leaching: HYPONATREMIA & │
- │ Complications │ HYPOCHLOREMIA (hypotonic solution draws out ions) │
- │ │ • Permanent black/brown staining of skin, floors, beds │
- │ │ • Rare METHEMOGLOBINEMIA (nitrate-reducing bacteria) │
- └───────────────────────┴────────────────────────────────────────────────────────┘
Clinical Management of Silver Nitrate Complications:
Electrolyte Leaching & Hypotonicity: A 0.5% silver nitrate solution is profoundly hypotonic ( 29.4 mOsm/L ~29.4\text{ mOsm/L} 29.4 mOsm/L ). When applied over extensive open burn surfaces, water diffuses into the body while sodium ( N a + Na^+ N a + ) and chloride ( C l − Cl^- C l − ) rapidly leach across the concentration gradient into the dressing. This causes severe hyponatremia , hypochloremia , and water intoxication. Serum electrolytes must be monitored every 6 to 12 hours, with proactive oral/IV sodium and chloride repletion.
Methemoglobinemia: Rare gastrointestinal or burn wound bacteria (e.g., Pseudomonas , Enterobacter , Proteus ) reduce nitrate ( N O 3 − NO_3^- N O 3 − ) to nitrite ( N O 2 − NO_2^- N O 2 − ). Absorbed nitrite oxidizes ferrous iron ( F e 2 + Fe^{2+} F e 2 + ) to ferric iron ( F e 3 + Fe^{3+} F e 3 + ) in hemoglobin, forming methemoglobin , which cannot bind oxygen. If the patient presents with cyanosis unresponsive to 100% oxygen and chocolate-brown arterial blood, obtain a co-oximetry panel. Treat with IV Methylene Blue ( 1 to 2 mg/kg 1\text{ to }2\text{ mg/kg} 1 to 2 mg/kg over 5 minutes).
Black Oxidation Staining: Silver nitrate oxidizes upon exposure to light and air, permanently staining skin (harmless epidermal stain that sloughs in weeks), linens, equipment, and walls black. Nursing staff must protect environmental surfaces with plastic sheeting.
5. Modern Nanocrystalline Silver Dressings (Acticoat, Aquacel Ag, Mepilex Ag)
Modern burn wound care has evolved toward advanced nanocrystalline silver dressings that overcome the limitations of traditional topical creams. NANOCRYSTALLINE SILVER DRESSING TECHNOLOGY
- ┌────────────────────────────────────────────────────────────────────────┐
- │ Physical Composition: Two layers of high-density polyethylene mesh │
- │ coated with nanocrystalline elemental silver (Ag0) around a rayon core.│
- ├────────────────────────────────────────────────────────────────────────┤
- │ Continuous Silver Ion Release: Releases steady therapeutic levels of │
- │ ionized silver (Ag+; 70–100 ppm) continuously over 3 to 7 days. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ Antimicrobial Spectrum: Rapid bactericidal action against MRSA, VRE, │
- │ multi-drug resistant Pseudomonas, and fungi within 30 minutes. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ Major Clinical Benefit: Dramatically reduces frequency of painful │
- │ dressing changes (changed every 3–7 days instead of BID). │
- └────────────────────────────────────────────────────────────────────────┘
- The Critical Activation Rule: Sterile Water vs. Normal Saline
Important
Nanocrystalline silver dressings (such as Acticoat) MUST ALWAYS be moistened and activated with STERILE WATER, NEVER 0.9% Normal Saline . Ag + (Active Silver Ion) + Cl − (Chloride from Saline) ⟶ AgCl ↓ (Insoluble Silver Chloride Precipitate) \text{Ag}^+\text{ (Active Silver Ion)} + \text{Cl}^-\text{ (Chloride from Saline)} \longrightarrow \text{AgCl}\downarrow\text{ (Insoluble Silver Chloride Precipitate)} Ag + (Active Silver Ion) + Cl − (Chloride from Saline) ⟶ AgCl ↓ (Insoluble Silver Chloride Precipitate)
If 0.9% Normal Saline is used to wet the dressing, the high concentration of chloride ions binds to the silver ions, instantly precipitating them into insoluble, inert silver chloride ( A g C l AgCl A g Cl ) . This completely extinguishes the dressing's antimicrobial efficacy.
Furthermore, sterile water activation releases silver radicals that exert potent anti-inflammatory effects, downregulating matrix metalloproteinases (MMPs) and accelerating wound re-epithelialization.
6. Non-Silver Topicals for Specialized Anatomical Sites
Topical Agent Composition & Spectrum Primary Burn Indications Clinical Practice Highlights
Bacitracin Gram-positive coverage ( Streptococcus , Staphylococcus ) Superficial partial-thickness facial burns; healing donor sites; post-graft margins Clear ointment allowing direct continuous wound visualization; non-toxic to corneal epithelium; painless.
Polymyxin B / Bacitracin (Polysporin) Gram-positive and Gram-negative ( Pseudomonas ) Periorbital burns, facial burns, autograft contact layer Safe near mucous membranes and eyes; avoids black staining and pseudoeschar; soothing.
Mupirocin 2% (Bactroban) Selective for MRSA and Gram-positive cocci Targeted treatment of confirmed MRSA colonization or localized donor site pustules Restrict use to documented MRSA to prevent emergence of mupirocin resistance; avoid large open surfaces.
Triple Antibiotic Ointment (Neomycin / Polymyxin / Bacitracin) Broad Gram-positive & Gram-negative coverage Minor partial-thickness burns; outpatient facial burns Neomycin carries high contact dermatitis risk (up to 10%) ; discontinue immediately if erythematous peri-wound rash develops.
Nystatin Ointment / Powder Selective antifungal against Candida albicans Fungal overgrowth in intertriginous burn regions (groin, axilla, inframammary) Frequently combined 1:1 with antibacterial creams during prolonged broad-spectrum therapy.
7. Comprehensive Topical Antimicrobial Matrix
Formulation Brand Name Eschar Penetration Dressing Frequency Key Adverse Reactions Contraindications & Warnings
Silver Sulfadiazine 1% Silvadene None (surface only) 1–2 times daily Transient leukopenia, pseudoeschar Sulfa allergy, pregnancy at term, neonates < 2 months <2\text{ months} < 2 months
Mafenide Acetate 8.5% Sulfamylon Cream Deep / Superior 1–2 times daily Severe burning pain, metabolic acidosis Carbonic anhydrase inhibition; monitor ABG for tachypnea
Mafenide Acetate 5% Sulfamylon Solution Deep / Superior Continuous wet soaks Stinging pain, metabolic acidosis Sulfa allergy, systemic acidemia
Silver Nitrate 0.5% AgNO3 Solution None (surface only) Wet soaks q2h; change q12–24h Severe hyponatremia, hypochloremia, black staining Hypotonicity electrolyte leaching, methemoglobinemia
Nanocrystalline Silver Acticoat / Aquacel Ag Surface / sustained Every 3–7 days Mild transient stinging Do NOT wet with 0.9% Saline (must use Sterile Water)